5-Chloro-N-{[(5S)-3-(6-methylthieno[2,3-b]pyridin-2-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}-2-thiophenecarboxamide | 348626-12-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 5-Chloro-N-{[(5S)-3-(6-methylthieno[2,3-b]pyridin-2-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}-2-thiophenecarboxamide
• 英文别名: 5-chloro-N-[[(5S)-3-(6-methylthieno[2,3-b]pyridin-2-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide
• CAS: 348626-12-0
• 化学式: C₁₇H₁₄ClN₃O₃S₂
• 分子量: 407.901
• InChiKey: CCFJTXMTRJOQLK-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (5S)-5-(aminomethyl)-3-(6-methylthieno[2,3-b]pyridin-2-yl)-1,3-oxazolidin-2-one 生成 5-Chloro-N-{[(5S)-3-(6-methylthieno[2,3-b]pyridin-2-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}-2-thiophenecarboxamide
  参考文献：
  名称：

  MICROANGIOPATHY TREATMENT AND PREVENTION

  摘要：

  本发明涉及选择性因子Xa抑制剂的使用，特别是公式(I)的噁唑烷酮，用于治疗和/或预防微血管病，并且它们用于生产用于治疗和/或预防微血管病的药物。

  公开号：

  US20100160301A1

文献信息

• COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES
  申请人：Perzborn Elisabeth

  公开号：US20100120718A1

  公开（公告）日：2010-05-13

  The present invention relates to combinations of A) oxazolidinones of the formula (I) with B) acetylsalicylic acid (aspirin) and C) an ADP receptor antagonist, in particular P 2 Y 12 purinoreceptor blocker, to a process for producing these combinations and to the use thereof as medicaments, in particular for the prophylaxis and/or treatment of thromboembolic disorders.

  本发明涉及A) 公式（I）的噁唑烷二酮与B) 乙酰水杨酸（阿司匹林）和C) ADP受体拮抗剂的组合物，特别是P2Y12嘌呤受体阻滞剂，以及制备这些组合物的方法和将其用作药物，特别是用于预防和/或治疗血栓栓塞性疾病。
• Substituted oxazolidinones and their in the field of blood coagulation
  申请人：——

  公开号：US20030153610A1

  公开（公告）日：2003-08-14

  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) 1 processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.

  这项发明涉及血液凝固领域。描述了一种新颖的一舁氧杂环丙烷衍生物，其一舁通式为（I）的制备方法以及它们作为药用活性化合物用于预防和/或治疗疾病的用途。
• Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders
  申请人：Perzborn Elisabeth

  公开号：US20080306070A1

  公开（公告）日：2008-12-11

  The present invention relates to combinations of A) oxazolidinones of the formula (I), with B) antiarrhythmics, processes for the production of these combinations, their use for the prophylaxis and/or treatment of diseases, and their use for the manufacture of medicaments for the prophylaxis and/or treatment of diseases, especially of thromboembolic disorders and/or complications.

  本发明涉及A) 具有化学式(I)的噁唑烷二酮与B) 抗心律失常药物的组合物，以及用于制备这些组合物的方法，它们用于预防和/或治疗疾病，并且用于制造用于预防和/或治疗疾病，特别是血栓栓塞性疾病和/或并发症的药物。
• Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation
  申请人：Straub Alexander

  公开号：US20060258724A1

  公开（公告）日：2006-11-16

  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.

  本发明涉及血凝领域。描述了一种新的氧唑啉衍生物，其通式为（I），以及它们的制备方法和用作药物活性化合物用于预防和/或治疗疾病的应用。
• SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION
  申请人：Straub Alexander

  公开号：US20080090815A1

  公开（公告）日：2008-04-17

  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.

  该发明涉及血凝领域。描述了一种新的氧杂环己酮衍生物的一般式（I），以及它们的制备方法和作为药物活性化合物用于预防和/或治疗疾病的用途。